R21 malaria vaccine is protective against intradermal but not intravenous Plasmodium falciparum sporozoites in a randomized controlled human malaria infection study in Kenyan adults
Kapulu, M. C.; Orenge, F.; Kimani, D.; Kibwana, E.; Kibet, H.; Mutahi, M.; Datoo, M. S.; Bellamy, D.; Musembi, J.; Ngoto, O.; Rashid, H.; Akinyi, S.; Mwatasa, M. H.; Nyamako, L.; Keter, K.; Gatheru, R.; Mutiso, A.; Musyoki, J.; Mwacharo, J.; Abebe, Y.; James, E. J.; Billingsley, P. F.; Ngetsa, C.; Mosobo, M.; Makale, J.; Tawa, B.; Wamae, K. K.; Ochola-Oyier, L. I.; Wambua, J.; Lawrie, A.; Ramos Lopez, F.; Roberts, R.; Richie, T. L.; Sim, B. K. L.; Hoffman, S. L.; Ewer, K. J.; Hill, A. V. S.; Hamaluba, M.; Bejon, P.
Show abstract
Both licensed Plasmodium falciparum malaria vaccines induce anti-circumsporozoite protein antibodies that block the malaria sporozoites injected by mosquitoes. Animal models show that sporozoites in the skin are more readily blocked than intravenous sporozoites. Controlled human malaria infections (CHMI) is usually done using infectious mosquito bites to predict efficacy in the field, but mosquito bites deliver a mixture of sporozoites into dermal layers and into capillaries. We undertook CHMI in volunteers vaccinated with the CSP-based R21/Matrix-M vaccine or with ME-TRAP-based viral vectored vaccines. R21/Matrix-M was highly protective against CHMI using intradermal inoculation of sporozoites (i.e. 0 out of 12 volunteers met treatment criteria) but not protective against direct venous inoculation (i.e. 5 out of 5 volunteers met treatment criteria). Volunteers vaccinated with viral vectors encoding ME-TRAP antigens were not protected against intradermal inoculation. Defining protective efficacy separately against direct venous inoculation and against intradermal inoculation enhances our mechanistic understanding of vaccination. The study was registered with the ClinicalTrials.gov (NCT03947190) and with PACTR (PACTR202108505632810).
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Accelerated prime-and-trap vaccine regimen in mice using repRNA-based CSP malaria vaccine 96%
- A vaccine targeting the L9 epitope of the malaria circumsporozoite protein confers protection from blood-stage infection in a mouse challenge model 96%
- An Epitope-based Malaria Vaccine Targeting the Junctional Domain of Circumsporozoite Protein 96%
Similar papers in this journal
- Genome, proteome, and immunome data explain why 6 month controlled human malaria infection with sporozoites of the Pf7G8 clone of Plasmodium falciparum is a rigorous predictor of the efficacy of the PfNF54-based PfSPZ Vaccine in Africa 96%
- Projected health impact of post-discharge malaria chemoprevention among children with severe malarial anaemia in Africa 94%
- A Second Generation Leishmanization Vaccine with a Markerless Attenuated Leishmania major Strain using CRISPR gene editing 93%
Similar papers in this journal
- SARS-CoV-2 variants: levels of neutralisation required for protective immunity 92%
- Safety and immunogenicity of a recombinant DNA COVID-19 vaccine containing the coding regions of the spike and nucleocapsid proteins: Preliminary results from an open-label, phase 1 trial in healthy adults aged 19–55 years 92%
- Determinants of passive antibody effectiveness in SARS-CoV-2 infection 91%
Similar papers in this journal
- Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada 91%
- Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial 91%
- BNT162b2 mRNA Vaccine Effectiveness Given Confirmed Exposure; Analysis of Household Members of COVID-19 Patients 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.